Articles

Marketing authorisation holders (MAHs) are required to take specific actions regarding their product licenses in Northern Ireland (NI) and Great Britain (GB) by 30 September 2024 to avoid potential regulatory complications.

In the EU, there are regulations - lots of them. There's even a specific regulation for micro, small and medium-sized enterprises (SMEs) in the pharma sector. The EU is seeking opinions on support for pharmaceutical SMEs.

The UK Government has recently allocated substantial funding of over £100 million to support five new quantum research hubs across the UK.

When a licensee entered into a trade mark licence for 25 years and decided five years in that they did not want to use the trade mark any more, they were still required to pay the large minimum royalties, the Court of Appeal has ruled.

Over a month has passed since the 2024 PING conference, providing invaluable insights into the uptake of AI in Pharma, its transformational promise, and the accompanying risks and pitfalls. Below is a summary of our key takeaways.

For life sciences companies processing health or genetic data, useful lessons can be taken from the 23andMe data breach, which is back in the spotlight thanks to a joint investigation by the UK and Canadian data protection authorities.